This earnings decrease was mainly driven by a one-time acquired in-process research and development charge related to Pfizer's licensing deal with 3SBio (TRSBF +0.00%). Without the impact of this ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three ...

More than a year after Pfizer and venture capital company Flagship Pioneering struck a partnership investing in 10 life sciences programs, the two unveiled a collaboration with Quotient Therapeutics.

Founded in 1849, Pfizer (NYSE: PFE) has transformed the lives of patients and shareholders alike. The pharmaceutical titan has been one of the best-performing stocks since the end of World War II, ...